Sign in to fuzzto save your conversations, follow your research and come back anytime.
Jubilant Pharmova
SectorHealthcare
Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and Allergy Therapy Products. It has 6 US FDA approved manufacturing facilities in India, USA and Canada, and a network of over 48 radiopharmacies in the USA. Jubilant Pharmova provides drug discovery and development services, and is working on addressing unmet medical needs in oncology and autoimmune diseases. The company has filed numerous Drug Master Files in various countries and has expanded its manufacturing and research capabilities in recent years.
In the news
Jubilant Pharmova approves ₹800 cr NCD issue; Quant MF exits
CRDMO Wars: Jubilant vs Sai Life Sciences
Jubilant Pharmova's US CMO facility gets VAI classification
Jubilant Pharmova gets USFDA approval for new fill-and-finish line
Jubilant Pharmova Q1 profit drops 45% to ₹56.5 crore
Jubilant Pharmova gets USFDA nod for Pantoprazole suspension
USFDA Completes Inspection of Jubilant HollisterStier Unit
Jubilant Pharmova Q4 profit drops 21% to ₹119.3 cr, Nuvama maintains BUY
Market Rally Continues: 6 stocks for March 25 amid Iran de-escalation
Company insights, generated from the most recent coverage.
Jubilant's proven deleveraging from 2.93x (Mar-23) to 1.1x (Mar-25) gives credibility to its zero-net-debt-by-FY30 pledge despite the current build-up.
Interest coverage of just 5.1x (FY25) is adequate but tight — it caps how much more debt Jubilant can take before the >20% ROCE ambition gets financially risky.
Net debt-to-EBITDA rose from 1.1x (Mar-25) to 1.5x (Sep-25) on ₹1,897 Cr net debt — a deliberate re-leveraging into Radiopharma, CDMO sterile injectables and CRDMO, not distress.